



PATIENT

Cooper Kelsey

SPECIES

Canine

BREED

Whippet

SEX

Male Neutered

AGE

14 years

WEIGHT

32.8lbs; 14.9kgs

INTERPRETED BY

Maggie Machen Lamy,
DVM, DACVIM
(Cardiology)

IMAGING PERFORMED BY

Melissa Weisman, DVM

HOSPITAL NAME

Minnesota Veterinary
Ultrasound

REFERRING VET

Dr. Weisman

INVOICE

28031

DATE

12/30/22

PRESENTING CLINICAL SIGNS

History: Recheck echo. Asymptomatic. BP: 135, 141, 120, 134, 135mmHg.
-Pertinent previous echo findings (5/2022 MML): Mod MR, moderate LA/LVE, no TR> LA; 3.5, LV: 4.5.

RADIOGRAPHIC FINDINGS *NOTE: Images submitted for supplemental cardiac information only.
Mild cardiomegaly. No obvious evidence of CHF.

ECHOCARDIOGRAM FINDINGS

2D, m-mode, color flow and doppler imaging is available. Diffuse thickening of mitral valve leaflets with no prolapse into the left atrial lumen. Moderate eccentric mitral regurgitation with moderate left atrial dilation. Normal MR velocity. Moderately increased LV diameter with adequate myocardial function. The tricuspid valve appears normal with no tricuspid regurgitation. Normal right atrial and ventricular diameter and morphology indicating no overt evidence of pulmonary arterial hypertension. The pulmonic and aortic valves are normal in morphology and mobility. Normal pulmonic and aortic outflow velocities with laminar flow. No aortic or no pulmonic insufficiency. No pericardial or pleural effusion noted. No obvious cardiac masses.

CARDIAC CHART

CANINE CARDIAC PARAMETERS	MR VMAX (m/s)	TR VMAX (m/s)	LA/AO (Boon method)	LA/AO (Heart Base; Swe)	FS (%)	EF (%)	EPSS (cm)
NORMAL PARAMETER	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6
PATIENT	5.4	NA	NM	1.8	46	78	NM
CANINE CARDIAC PARAMETERS	HR (BPM)	AV VMAX (m/s)	PV MAX (m/s)	BODY WEIGHT (kg)	LA 2D short axis Base view (cm)	LVIDd Avg; 2D and m-mode short axis (cm)	LVIDs Avg; 2D and m-mode short axis (cm)
NORMAL PARAMETER	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW
PATIENT	110	1.4	0.6	14.9	3.7	4.0	2.1
*Normal chamber parameters expressed as a mean value (SD)							
BODY WEIGHT DEPENDENT PARAMETERS							
<i>*Note: All measurements based upon multi-modal images and methods. An average value is reported.</i>							
Adapted from June Boon, Veterinary Echocardiography, 1998				5	1.27 (5.3)	2.46 (2.46)	1.36 (5.5)
Rishniw M and Hollis NE, J Vet Intern Med 2000; 14:429-435				10	1.40 (4.5)	2.74 (5.2)	1.60 (4.7)
Hansson et al, Vet Rad and Ultrasound 2002				15	1.50 (3.8)	3.27 (3.5)	2.06 (3.1)
Bonagura et al. Echocardiography: principles of interpretation, Vet Clin North Am 15:1177, 1995				20	1.83 (2.0)	3.71 (2.4)	2.43 (2.1)
				25	2.02 (1.9)	4.14 (2.2)	2.80 (2.0)
				30	2.18 (2.4)	4.48 (2.9)	3.10 (2.5)
				35	2.33 (3.3)	4.83 (3.9)	3.39 (3.4)
				40	2.48 (4.3)	5.17 (5.0)	3.69 (4.5)
				45	2.62 (5.2)	5.48 (6.1)	3.96 (5.4)
				50	2.88 (7.1)	6.07 (8.3)	4.46 (7.4)

INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS

Chronic degenerative valve disease persists with evidence of stability. Moderate mitral regurgitation is unchanged, without progressive left heart enlargement. Persistently moderate left atrial enlargement indicates there is relatively low risk for imminent complication, however risk for progression to spontaneous congestive heart failure in the future is elevated. No additional issues are identified.



PATIENT

Cooper Kelsey

Reasonable to continue Pimobendan lifelong as prescribed with no obvious indication for additional medications. Continued assessment of progression is recommended, with a guarded prognosis (stage B2). Patient may be at risk for development of CHF, arrhythmias, and/or sudden death going forward.

SPECIES

Canine

Omega fatty acid supplementation and mild salt restriction may also be of some long-term benefit. Monitor for development of a progressive cough, labored breathing, exercise intolerance or collapse episodes.

BREED

Whippet

Anesthetic risk remains mildly elevated. Cardiac protective drug choices (opioid/benzodiazepine premedication, Propofol or alfaxalone induction, iso or sevo gas) are recommended. Monitor for arrhythmias, hypotension, and hypoxia both intra and post-operatively and intervene as necessary. Judicious IV fluid rates are recommended to avoid fluid overload. Avoid heart rate stimulating drugs such as atropine unless clinically indicated.

SEX

Male Neutered

AGE

14 years

PLAN

Baseline BP recommended every 6 months. Continue Pimobendan 0.25-0.3mg/kg PO q12h.

Recommend monitor for progression with a recheck echocardiogram in 6 months, sooner if any development of clinical signs.


WEIGHT

32.8lbs; 14.9kgs

IMAGES

INTERPRETED BY

Maggie Machen Lamy,
DVM, DACVIM
(Cardiology)



IMAGING PERFORMED BY

Melissa Weisman, DVM

HOSPITAL NAME

Minnesota Veterinary
Ultrasound

The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

REFERRING VET

Dr. Weisman

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance, please contact me.

INVOICE

28031

Maggie Machen Lamy, DVM
Diplomate of the American College of Veterinary Internal Medicine (Cardiology)
info@sonopath.com

DATE

12/30/22